Triphala ameliorates hyperuricemia-associated nephropathy by modulating the gut microbiota-glycerophospholipid-TLR4 axis
Phytomedicine · 2026-10 · 160 · 158694
DOI: 10.1016/j.phymed.2026.158694 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2026-10. Verfasst von Cong Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: International Cooperation Base for Active Substances in Traditional Chinese Medicine in Hubei Province, School of Pharmaceutical Sciences, South-Cent…. Hauptthemen laut MEDLINE: Hyperuricemia, Toll-Like Receptor 4, Gastrointestinal Microbiome, Kidney Diseases. Die Arbeit nennt 57 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, Hubei Province Department of Science and Technology, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Hyperuricemia (HUA) is a metabolic disorder with an escalating global prevalence, and its progression to HUA-associated nephropathy represents an important contributor to chronic kidney injury. Emerging evidence highlights a bidirectional relationship between uric acid and lipid metabolism, with dyslipidemia contributing to the pathological progression of HUA-related complications. Triphala (TRP), a classic Tibetan herbal formula with broad metabolic regulatory properties, was selected as a potential intervention for the complex metabolic disturbances associated with HUA. However, its therapeutic efficacy and the precise molecular mechanisms underlying its effects in HUA remain to be fully elucidated. PURPOSE: This study aimed to investigate the protective effects of TRP on hyperuricemia-associated nephropathy and to elucidate the underlying mechanisms. METHODS: High-performance liquid chromatography (HPLC) was first employed to identify and quantify seven representative constituents in the TRP aqueous extract. To evaluate the efficacy of TRP, an HUA mouse model was established through the combined administration of intraperitoneal potassium oxonate injections and a yeast-containing diet. A multi-omics strategy integrating 16S rRNA sequencing, metabolomics and lipidomics elucidated TRP's impact on the gut microbiota and host metabolism. Critically, fecal microbiota transplantation (FMT), TLR4 blockade experiments, and in vitro assays were employed to evaluate the contribution of TRP-modulated microbiota and the LPC-TLR4 pathway to the protective effects of TRP. RESULTS: HPLC identified chebulic acid, gallic acid, and corilagin as the major representative constituents of TRP aqueous extract. TRP dose-dependently reduced serum uric acid, improved renal function by lowering serum creatinine (Cr) and blood urea nitrogen (BUN) levels, increased the fractional excretion of uric acid (FEUA), and alleviated tubular injury and fibrosis. These improvements were accompanied by normalized urate transporters (downregulated URAT1/GLUT9; restored OAT1/OAT3) and suppressed renal inflammatory cytokines. Multi-omics analysis revealed that TRP reversed HUA-induced dysbiosis by suppressing opportunistic pathogens (e.g., Parasutterella, Allobaculum) and enriching beneficial genera (e.g., Bifidobacterium, Akkermansia), specifically reducing pro-inflammatory LPC (e.g., LPC16:0, LPC18:1). TRP and FMT effectively inhibited the TLR4/MyD88/NF-κB signaling axis and reduced LPC accumulation within the kidney. In vitro experiments validated that these specific LPC directly trigger TLR4 expression and TNF-α release, confirming the potential role of the microbiota-driven lysophospholipid-TLR4 pathway in HUA-associated chronic renal inflammation. CONCLUSION: TRP ameliorates HUA and renal inflammation by remodeling the gut microbiota to suppress the aberrant accumulation of pro-inflammatory lysophospholipids, thereby deactivating the TLR4-mediated inflammatory cascade. These findings establish the gut microbiota-glycerophospholipid metabolism-renal inflammation axis as a potential therapeutic target and validate TRP as a relevant strategy for targeting the gut microbiome to treat systemic metabolic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- International Cooperation Base for Active Substances in Traditional Chinese Medicine in Hubei Province, School of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, China.
- Department of Rheumatology & Immunology, Laboratory of Rheumatology & Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.
- School of Pharmacy, Hubei Shizhen Laboratory, Hubei University of Chinese Medicine, Wuhan 430065, China.
- School of Pharmacy, Hubei Shizhen Laboratory, Hubei University of Chinese Medicine, Wuhan 430065, China; Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, School of Pharmacy, Hubei University of Chine…
- International Cooperation Base for Active Substances in Traditional Chinese Medicine in Hubei Province, School of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, China. Electronic address: clyhapp…
Förderung
- Fundamental Research Funds for the Central Universities
- Hubei Province Department of Science and Technology
- National Natural Science Foundation of China
- South-Central Minzu University
- Hubei Province Natural Science Foundation
Zitieren
APA
Liu, C., Zhang, H., Zhang, H., Zhao, Y., Wu, C., Lin, Q., Luo, Y., Wei, L., Chen, J., Rao, X., Xiong, S., Shen, H., Hong, S., Shi, Z., Yin, S., Lan, Z., & Chen, L. (2026). Triphala ameliorates hyperuricemia-associated nephropathy by modulating the gut microbiota-glycerophospholipid-TLR4 axis. Phytomedicine, 160, 158694. https://doi.org/10.1016/j.phymed.2026.158694
Vancouver
Liu C, Zhang H, Zhang H, Zhao Y, Wu C, Lin Q, et al. Triphala ameliorates hyperuricemia-associated nephropathy by modulating the gut microbiota-glycerophospholipid-TLR4 axis. Phytomedicine. 2026;160:158694. doi:10.1016/j.phymed.2026.158694
BibTeX
@article{Liu2026,
author = {Liu, Cong and Zhang, Huan and Zhang, Huihui and Zhao, Yi and Wu, Chen and Lin, Qinxiong and Luo, Yubin and Wei, Liangkai and Chen, Jianqiu and Rao, Xinyu and Xiong, Siyi and Shen, Hanmeng and Hong, Shuyan and Shi, Zhaohua and Yin, Shijin and Lan, Zhou and Chen, Lvyi},
title = {Triphala ameliorates hyperuricemia-associated nephropathy by modulating the gut microbiota-glycerophospholipid-TLR4 axis},
journal = {Phytomedicine},
year = {2026},
volume = {160},
pages = {158694},
doi = {10.1016/j.phymed.2026.158694}
}
EUVIMED